Skip to main content

Table 1 Patient and tumour characteristics

From: Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Characteristic

No. of Patients

(n = 39)

%

Age (years)

Median

63

Range

38-80

Gender

Male

30

77

Female

9

23

ECOG performance status

0

16

41

1

17

44

2

6

15

Disease status

Locally advanced

0

0

Metastatic

39

100

Site of the primary tumour

Oesophago-gastric junction

22

56

Stomach

17

44

Histological classification (Laurén)

Intestinal

22

56

Non-intestinal (diffuse or mixed)

17

44

  1. Abbreviation: ECOG Eastern Cooperative Oncology Group